News
HotCopper on MSN50m
Prescient Therapeutics CEO highlights PTX-100 progress in RAS-Driven cancer trialIn this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a first-in-class therapy targeting the RAS pathway in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback